As of June 18, 2026, CytomX Therapeutics's top three insider holders are Sean A. Mccarthy (Ceo, 1.08Mn shares), Sean A. Mccarthy (Ceo, 987.89K shares), Marcia Belvin (Svp, Chief Scientific Officer, 300.76K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Lloyd A Rowland | General Counsel | 120,594 | 0 | 20 Mar, 2025 |
| Elaine V Jones | - | 5,142 | 0 | 31 Mar, 2023 |
| Alison L. Hannah | Chief Medical Officer | 31,898 | 0 | 21 Jul, 2022 |
| Sean A. Mccarthy | Ceo | 1,078,922 | 0 | 19 Mar, 2026 |
| Amy C. Peterson | Evp, Chief Development Officer | 58,433 | 0 | 20 Mar, 2023 |
| Carlos Campoy | Chief Financial Officer | 38,224 | 0 | 20 Mar, 2023 |
| Yu-Waye Chu | Chief Medical Officer | 189,446 | 0 | 19 Mar, 2026 |
| Christopher Ogden | Chief Financial Officer | 296,948 | 0 | 19 Mar, 2026 |
| Jeffrey B Landau | Chief Business Officer | 119,056 | 0 | 22 Aug, 2024 |
| Marcia Belvin | Svp, Chief Scientific Officer | 300,760 | 0 | 19 Mar, 2026 |
| Rachael Lester | Chief Business Officer | 20,000 | 0 | 04 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 17 Mar, 2026 | Christopher Ogden | Common Stock | D | 19,323 | $6.42 | 296,948 | D | S |
| 17 Mar, 2026 | Sean A. Mccarthy | Common Stock | D | 118,969 | $6.42 | 1,078,922 | D | S |
| 17 Mar, 2026 | Christopher Ogden | Common Stock | D | 19,323 | $6.42 | 296,948 | D | S |
| 17 Mar, 2026 | Sean A. Mccarthy | Common Stock | D | 118,969 | $6.42 | 1,078,922 | D | S |
| 17 Mar, 2026 | Yu-Waye Chu | Common Stock | D | 21,279 | $6.42 | 189,446 | D | S |
| 17 Mar, 2026 | Marcia Belvin | Common Stock | D | 31,492 | $6.42 | 300,760 | D | S |
| 02 Feb, 2026 | Sean A. Mccarthy | Common Stock | A | 210,000 | $0.00 | 1,197,891 | D | A |
| 02 Feb, 2026 | Rachael Lester | Common Stock | A | 20,000 | $0.00 | 20,000 | D | A |
| 02 Feb, 2026 | Christopher Ogden | Common Stock | A | 90,000 | $0.00 | 316,271 | D | A |
| 02 Feb, 2026 | Christopher Ogden | Common Stock | A | 90,000 | $0.00 | 316,271 | D | A |
| 02 Feb, 2026 | Yu-Waye Chu | Common Stock | A | 75,000 | $0.00 | 210,725 | D | A |
| 02 Feb, 2026 | Sean A. Mccarthy | Common Stock | A | 210,000 | $0.00 | 1,197,891 | D | A |
| 02 Feb, 2026 | Rachael Lester | Common Stock | A | 20,000 | $0.00 | 20,000 | D | A |
| 02 Feb, 2026 | Marcia Belvin | Common Stock | A | 60,000 | $0.00 | 332,252 | D | A |
| 02 Feb, 2026 | Rachael Lester | Stock Option (Right to Buy) | A | 50,000 | $0.00 | 50,000 | D | A |
| 02 Feb, 2026 | Marcia Belvin | Stock Option (Right to Buy) | A | 250,000 | $0.00 | 250,000 | D | A |
| 02 Feb, 2026 | Christopher Ogden | Stock Option (Right to Buy) | A | 325,000 | $0.00 | 325,000 | D | A |
| 02 Feb, 2026 | Christopher Ogden | Stock Option (Right to Buy) | A | 325,000 | $0.00 | 325,000 | D | A |
| 02 Feb, 2026 | Yu-Waye Chu | Stock Option (Right to Buy) | A | 300,000 | $0.00 | 300,000 | D | A |
| 02 Feb, 2026 | Rachael Lester | Stock Option (Right to Buy) | A | 50,000 | $0.00 | 50,000 | D | A |